MedTrace Logo

Shanghai ST-segment Elevation Myocardial Infarction Cohort

NCT05450757 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-07-11

No results posted yet for this study

Summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy.

This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Conditions

  • ST Elevation Myocardial Infarction

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Wei Wei Quan, M.D.,Ph.D. · Ruijin Hospital

  • Tian Qi Zhu, M.D.,Ph.D. · Ruijin Hospital

  • Xiao Xiang Yan, M.D.,Ph.D. · Ruijin Hospital

  • Wen Li Zhang, M.D.,Ph.D. · Ruijin Hospital

  • Run Du, M.D.,Ph.D. · Ruijin Hospital

  • Ying Jia Xu, M.D.,Ph.D. · Fudan University

  • Wei Hu · Shanghai Minhang District Central Hospital

  • Yimeng Zhou · Tongji University

  • Zongjun Liu · Shanghai Putuo District Central Hospital

  • Xiangdong Xu · Shanghai Jiading District Central Hospital

  • Zengyong Qiao · Shanghai Fengxian District Central Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-12
Primary Completion
2023-09-17
Completion
2024-09-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450757 on ClinicalTrials.gov